Kymera Therapeutics, Inc. · NASDAQ:KYMR
Kymera Therapeutics — AAD Annual Meeting 2026
16 slides from Kymera Therapeutics's conference presentation, Mar 28, 2026
Slide 1: Clinical Activity and Safety of KT-621, an Oral STAT6 Degrader, in Moderate-to-Severe Atopic Dermatitis
March 28, 2026 Clinical Activity and Safety of KT-621, an Oral STAT6 Degrader, in Moderate-to-Severe Atopic Dermatitis: Phase 1b Trial Results Jared Gollob,1 Heather Paleczny,1 Michael Blankinship,2 Paul Yamauchi,3 Vlada Groysman,4 Neil Graham,1 Joyoti Dey,1 Sagar Agarwal,1 Kelvin Shi,1 Mahta Mortez
Slide 2: Targeted Protein Degradation: Achieving Biologics-like Activity with Oral Medicines
Targeted Protein Degradation: Achieving Biologics-like Activity with Oral Medicines Targeted Protein Degradation (TPD) Mechanism of Action Degraders Enable Continuous, Complete Pathway Blockade Harnessing the E3 Ubiquitin Proteasome System Superior to Traditional Small Molecule Inhibitors 1 2 3 4 Sm
Slide 3: STAT6: Highly Validated, Historically Undrugged Target for Type 2 Inflammatory Diseases
STAT6: Highly Validated, Historically Undrugged Target for Treatment of Type 2 Inflammatory Diseases STAT6 KT-621 TRANSCRIPTION FACTOR FIRST-IN-CLASS ORAL STAT6 DEGRADER6 • STAT6 is the specific transcription factor in the IL-4/IL-13 pathway1-3 Dupilumab IL-4 Dupilumab IL-4 IL-13 • IL-4/IL-13 is cli
Slide 4: BroADen Phase 1b Study Design
KT-621 BroADen Phase 1b Study Design Open-label, multicenter, single-arm study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of oral KT-621 in adults with moderate to severe atopic dermatitis Each Cohort Dosed for 28 Days 14 Days Screening Endpoints
Slide 5: BroADen Phase 1b Demographics and Baseline Characteristics
KT-621 BroADen Phase 1b Demographics and Baseline Characteristics Generally Well-Balanced Across Treatment Cohorts Patient Demographics Patient Baseline Characteristics 100 mg 200 mg Overall 100 mg 200 mg Overall (n=10) (n=12) (n=22) (n=10) (n=12) (n=22) Gender, n (%) vIGA-ADTM, n (%) Female 6 (60)
Slide 6: Achieved Deep STAT6 Degradation in Blood and Skin
KT-621 Achieved Deep STAT6 Degradation in Blood and Skin Degradation Maintained for 28 Days Across Both Dose Cohorts Median STAT6 Degradation in Blood Median STAT6 Degradation in Skin Method: Flow Cytometry Method: Targeted Mass Spectrometry % STAT6 Change from Baseline % STAT6 Change from Baseline
Slide 7: Disease-Relevant Biomarkers of Type 2 Inflammation
Disease-Relevant Biomarkers of Type 2 Inflammation TARC (CCL17) Eotaxin-3 (CCL26) IgE IL-31 • TARC drives chemotaxis • Eotaxin-3 drives chemotaxis • IgE activates mast cells and • IL-31 is a key pruritogenic of CCR4-expressed T cells of CCR3-expressed basophils to release Type 2 cytokine produced by
Slide 8: Achieved Median TARC Reduction of up to 74%
KT-621 Achieved Median TARC Reduction of up to 74% Stratified by Dose Stratified by Baseline TARC (1600 pg/mL) KT-621 100 mg QD (n=10) High BL TARC (n=6) Median 2356 pg/mL KT-621 200 mg QD (n=12) Low BL TARC (n=16) Median 701 pg/mL Median % Change from Baseline Median % Change from Baseline in Serum
Slide 9: Impacted Multiple Additional Type 2 Biomarkers
KT-621 Impacted Multiple Additional Type 2 Biomarkers Median % Change from Median % Change from Median % Change from Baseline in Eotaxin-3 Baseline in IgE Baseline in IL-31 KT-621 100 mg QD (n=7) KT-621 100 mg QD (n=10) KT-621 100 mg QD (n=8) KT-621 200 mg QD (n=11) KT-621 200 mg QD (n=12) KT-621 20
Slide 10: Achieved Mean EASI Reduction of up to 63% by Week 4
KT-621 Achieved Mean EASI Reduction of up to 63% by Week 4 Mean % Change from Baseline in EASI Mean % Change in EASI: Stratified by Baseline EASI Mean (±SE) Percent Change from Mean (±SE) Percent Change from 0 0 KT-621 100 mg QD (n=10)* BL EASI ≥ 22 (n=12)† Mean baseline EASI=31 Baseline in EASI Sco
Slide 11: Improved Disease Burden: EASI-50, EASI-75, and vIGA-AD 0 or 1 at Week 4
KT-621 Substantially Improved Disease Burden as Measured by EASI-50, EASI-75, and vIGA-ADTM 0 or 1 at Week 4 EASI-50 and EASI-75 vIGA-AD 0 or 1 Responders 100 KT-621 100 mg QD (n=9) 50 KT-621 200 mg QD (n=12) 83% KT-621 Overall (n=21) 80 76% 40 67% Responders (%) Responders (%) 60 30 22% 40 20 19% 3
Slide 12: Robust Improvements in BSA, Peak Pruritus, and POEM
KT-621 Achieved Robust and Consistent Improvements in BSA, Peak Pruritus, and Patient Reported Severity of Disease (POEM) Mean % Change Mean % Change in Peak Mean Change in in Total BSA Pruritus NRS POEM KT-621 100 mg QD (n=9) KT-621 100 mg QD (n=10) KT-621 100 mg QD (n=10) KT-621 200 mg QD (n=12) K
Slide 13: Phase 1b Safety Summary
KT-621 Phase 1b Safety Summary • Well-tolerated with favorable safety at both 100 mg and 200 mg • No SAEs or Severe AEs • No dose-dependent pattern in the TEAEs • No related TEAEs or TEAEs leading to discontinuation • No AEs of conjunctivitis (or of any ocular disorder), herpes infections, or arthra
Slide 14: KT-621: First Evidence of Clinical Activity and Safety of a STAT6-targeted Drug in Patients
KT-621: First Evidence Demonstrating Clinical Activity and Safety of a STAT6-targeted Drug in Patients with Atopic Dermatitis • Deep STAT6 degradation in blood and lesional skin • Robust suppression of Type 2 inflammation • Meaningful improvements across both clinician assessed and patient reported
Slide 15: KT-621: BROADEN2 Phase 2b Trial
KT-621: BROADEN2 Phase 2b Trial Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Dose-ranging Design • Randomized, double-blind, Key Trial Aim placebo-controlled • ~200 patients Establish clinical activity and • Daily dose for 16-weeks; safety in AD to select dose to Adult &
Slide 16: Thank You
Thank You For more information, please visit our Booth #3551 or www.kymeratx.com AAD Annual Meeting | Denver | March 27-31, 2026 16